TESARO Revenue and Competitors
Estimated Revenue & Valuation
- TESARO's estimated annual revenue is currently $17.3M per year.
- TESARO received $409.0M in venture funding in July 2016.
- TESARO's estimated revenue per employee is $201,000
- TESARO's total funding is $457M.
Employee Data
- TESARO has 86 Employees.
- TESARO grew their employee count by -14% last year.
TESARO's People
| Name | Title | Email/Phone |
|---|
TESARO Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is TESARO?
TESARO (NASDAQ: TSRO) is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community. For more information, please visit www.tesarobio.com.
keywords:Enterprise Software,Health It,Healthcare,Pharmaceuticals
$457M
Total Funding
86
Number of Employees
$17.3M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
TESARO News
Tesaro Inc.'s ex-board, backers at New Enterprise Associates Inc., and financial advisers at Citigroup Inc. secured their win against...
Tesaro Chairman David M. Mott was a general partner at NEA and led its health care practice, and NEA was preparing to start a new fund in 2019 ...
Consulting or Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, TESARO (Inst), VBL Therapeutics, Merck, Aravive, Eisai, Vavotar Life...
The spinout of GlaxoSmithKline’s consumer health unit could reportedly take the form of a $54 billion sale to private equity firms. It would mark a pivot from previous plans to turn that group into its own listed company — one in which current GSK shareholders can contin ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $23.2M | 86 | 39% | N/A |
#2 | $28.2M | 86 | -9% | N/A |
#3 | $30.5M | 87 | 18% | $20.1M |
#4 | $12.9M | 89 | 0% | $352.5M |
#5 | $13.1M | 90 | 5% | N/A |
TESARO Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-01-30 | $100.0M | Undisclosed | Multiple | Article |
| 2014-09-30 | $201.2M | Undisclosed | Citigroup | Article |
| 2015-03-11 | $179.7M | Undisclosed | Citigroup | Article |
| 2016-02-29 | $155.0M | Undisclosed | Kleiner Perkins | Article |
| 2016-04-22 | $50.0M | Undisclosed | Article | |
| 2016-07-01 | $345.0M | Undisclosed | Multiple | Article |
| 2016-07-11 | $409.0M | Undisclosed | Multiple | Article |